Healthcare Services

Rising prevalence of rare diseases is driving demand and growth in the hereditary angioedema market

April 22, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Hereditary Angioedema Market In 2026 And 2030?

The hereditary angioedema market size has shown substantial growth in recent years. It is projected to expand from $2.81 billion in 2025 to $3.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by increased clinical awareness of rare genetic disorders, the availability of plasma-derived C1 esterase inhibitors, the broadening of specialty treatment centers, enhanced diagnostic accuracy for HAE, and rising patient advocacy initiatives.

The hereditary angioedema market is anticipated to undergo significant expansion in the coming years. It is projected to achieve a value of $4.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This growth during the forecast period can be attributed to several factors, including the introduction of novel oral and subcutaneous treatments, increased investment in developing drugs for rare diseases, a growing embrace of personalized medicine strategies, the expansion of genetic screening programs, and improved long-term disease management approaches. Prominent trends for the forecast period include the increasing adoption of targeted bradykinin therapies, a rise in the use of prophylactic treatment regimens, an intensified focus on early genetic diagnosis, the expansion of home-based self-administration therapies, and enhanced patient-centric treatment methodologies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

What Key Factors Are Shaping The Hereditary Angioedema Market Landscape?

The expanding incidence of rare diseases is anticipated to advance the hereditary angioedema market in the coming years. Often referred to as orphan diseases, these are health conditions impacting a small segment of the global populace. Several factors contribute to the rising occurrence of rare diseases, including advancements in medical research, shifts in demographic profiles, and ecological influences. Hereditary angioedema (HAE) stands out as a critical rare disease, necessitating specialized interventions and heightened public knowledge because of its potentially fatal swelling episodes. Its uncommon and genetic origin underscores the criticality of prompt diagnosis and specific treatments for effective control and better patient results. As an illustration, in January 2025, The American Cancer Society, a professional organization based in the US, projected that around 59,660 new diagnoses of oral cavity and oropharyngeal cancer are expected in 2025, with approximately 12,770 individuals predicted to succumb to these cancers. Consequently, the increasing occurrence of rare diseases is fueling the expansion of the hereditary angioedema market.

What Segment Categories Shape The Hereditary Angioedema Market Segment Landscape?

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

What Market Trends Are Affecting The Hereditary Angioedema Market?

Leading companies in the hereditary angioedema market are actively developing innovative products, including oral plasma kallikrein inhibitors, to offer patients more convenient and effective on-demand treatment choices. Oral plasma kallikrein inhibitors are medications designed to block plasma kallikrein, thereby preventing excessive bradykinin production, and are primarily utilized for treating hereditary angioedema. For example, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced the FDA’s acceptance of its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat introduces a new treatment strategy by specifically targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA marks a significant achievement toward potential approval and commercialization.

Who Are The Companies Operating Across The Hereditary Angioedema Market Value Chain?

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

Get The Full Hereditary Angioedema Market Report:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Which Region Leads The Hereditary Angioedema Market In Overall Market Size?

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hereditary Angioedema Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2026, By The Business Research Company

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795